BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16258518)

  • 1. Chromogenic in situ hybridization-detected hotspot MYCN amplification associates with Ki-67 expression and inversely with nestin expression in neuroblastomas.
    Korja M; Finne J; Salmi TT; Kalimo H; Karikoski R; Tanner M; Isola J; Haapasalo H
    Mod Pathol; 2005 Dec; 18(12):1599-605. PubMed ID: 16258518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of MYCN gene amplification in neuroblastoma using chromogenic in situ hybridization (CISH): an alternative and practical method.
    Bhargava R; Oppenheimer O; Gerald W; Jhanwar SC; Chen B
    Diagn Mol Pathol; 2005 Jun; 14(2):72-6. PubMed ID: 15905689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of MYCN amplification with MCM7 protein expression in neuroblastomas: a chromogenic in situ hybridization study in paraffin sections.
    Tsai HY; Hsi BL; Hung IJ; Yang CP; Lin JN; Chen JC; Tsai SF; Huang SF
    Hum Pathol; 2004 Nov; 35(11):1397-403. PubMed ID: 15668898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of chromogenic in situ hybridization to identify MYCN gene copy number in neuroblastoma using routine tissue sections.
    Thorner PS; Ho M; Chilton-MacNeill S; Zielenska M
    Am J Surg Pathol; 2006 May; 30(5):635-42. PubMed ID: 16699319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
    Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S
    Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
    Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
    Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of MYCN amplification in patients with stage 4 neuroblastoma who undergo intensive chemotherapy.
    Suita S; Tajiri T; Kaneko M; Hirai M; Mugishima H; Sugimoto T; Tsuchida Y
    J Pediatr Surg; 2007 Mar; 42(3):489-93. PubMed ID: 17336185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of MYCN amplification status in Tunisian neuroblastoma: CISH and MLPA combining approach.
    H'Mida Ben Brahim D; Trabelsi S; Chabchoub I; Gargouri I; Harrabi I; Moussa A; Chourabi M; Haddaji M; Sassi S; Mougou S; Gribaa M; Ben Ahmed S; Zakhama A; Nouri A; Saad A
    Tunis Med; 2015; 93(8-9):527-31. PubMed ID: 26815518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma.
    Tanaka S; Tajiri T; Noguchi S; Shono K; Ihara K; Hara T; Suita S
    J Pediatr Surg; 2004 Jan; 39(1):63-8. PubMed ID: 14694373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
    Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
    Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas.
    Huang R; Cheung NK; Vider J; Cheung IY; Gerald WL; Tickoo SK; Holland EC; Blasberg RG
    FASEB J; 2011 Dec; 25(12):4138-49. PubMed ID: 21856782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Copy number gain of MYCN gene is a recurrent genetic aberration and favorable prognostic factor in Chinese pediatric neuroblastoma patients.
    Wang M; Zhou C; Cai R; Li Y; Gong L
    Diagn Pathol; 2013 Jan; 8():5. PubMed ID: 23320395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients.
    Chang HH; Tseng YF; Lu MY; Yang YL; Chou SW; Lin DT; Lin KH; Jou ST; Hsu WM; Jeng YM
    Mod Pathol; 2020 Apr; 33(4):531-540. PubMed ID: 31695155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional interplay between MYCN, NCYM, and OCT4 promotes aggressiveness of human neuroblastomas.
    Kaneko Y; Suenaga Y; Islam SM; Matsumoto D; Nakamura Y; Ohira M; Yokoi S; Nakagawara A
    Cancer Sci; 2015 Jul; 106(7):840-7. PubMed ID: 25880909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.
    Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M
    Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The calcium-sensing receptor is silenced by genetic and epigenetic mechanisms in unfavorable neuroblastomas and its reactivation induces ERK1/2-dependent apoptosis.
    Casalà C; Gil-Guiñón E; Ordóñez JL; Miguel-Queralt S; Rodríguez E; Galván P; Lavarino C; Munell F; de Alava E; Mora J; de Torres C
    Carcinogenesis; 2013 Feb; 34(2):268-76. PubMed ID: 23108190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant DDX1 and MYCN gain in neuroblastoma.
    Defferrari R; Tonini GP; Conte M; Papio F; Sementa AR; Valent A; Schena F; Perri P; Mazzocco K
    Cancer Lett; 2007 Oct; 256(1):56-63. PubMed ID: 17611020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2p24 Gain region harboring MYCN gene compared with MYCN amplified and nonamplified neuroblastoma: biological and clinical characteristics.
    Jeison M; Ash S; Halevy-Berko G; Mardoukh J; Luria D; Avigad S; Feinberg-Gorenshtein G; Goshen Y; Hertzel G; Kapelushnik J; Ben Barak A; Attias D; Steinberg R; Stein J; Stark B; Yaniv I
    Am J Pathol; 2010 Jun; 176(6):2616-25. PubMed ID: 20395439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group.
    Wang LL; Suganuma R; Ikegaki N; Tang X; Naranjo A; McGrady P; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Shimada H
    Cancer; 2013 Oct; 119(20):3718-26. PubMed ID: 23901000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas.
    Torres J; Regan PL; Edo R; Leonhardt P; Jeng EI; Rappaport EF; Ikegaki N; Tang XX
    Int J Oncol; 2010 Oct; 37(4):983-91. PubMed ID: 20811720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.